Cargando…

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis

Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lu, Li, Yanyan, Que, Ximei, Gao, Xue, Gao, Qian, Yu, Mingxing, Ma, Kaili, Xi, Yanfeng, Wang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908914/
https://www.ncbi.nlm.nih.gov/pubmed/29674626
http://dx.doi.org/10.1038/s41598-018-24631-5
_version_ 1783315791899262976
author Li, Lu
Li, Yanyan
Que, Ximei
Gao, Xue
Gao, Qian
Yu, Mingxing
Ma, Kaili
Xi, Yanfeng
Wang, Tong
author_facet Li, Lu
Li, Yanyan
Que, Ximei
Gao, Xue
Gao, Qian
Yu, Mingxing
Ma, Kaili
Xi, Yanfeng
Wang, Tong
author_sort Li, Lu
collection PubMed
description Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study followed the guidelines of PRISMA and Cochrane handbook. The hazard ratios (HRs) for overall survival (OS) were pooled to estimate the main effect size. Twenty studies recruited a total of 5576 patients were available for this meta-analysis. The results showed that MYC (HR = 1.96, 95%CI (confidence interval) = 1.69–2.27)without heterogeneity(I(2) = 17.2%, P = 0.280), BCL2 (HR = 1.65, 95%CI = 1.43–1.89, I(2) = 20.7%, P = 0.234) protein overexpression, and co-overexpression (HR = 2.58, 95%CI = 2.19–3.04, I(2) = 17.2%, P = 0.275) had a poor prognosis in R-CHOP treated DLBCL patients, respectively. The current analysis indicated that MYC and/or BCL2 protein overexpression, and particularly co-overexpression was related to short overall survival in R-CHOP treated DLBCL patients, showing that application of the two new biomarkers can help to better stratify DLBCL patients and guide targeted treatment.
format Online
Article
Text
id pubmed-5908914
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59089142018-04-30 Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis Li, Lu Li, Yanyan Que, Ximei Gao, Xue Gao, Qian Yu, Mingxing Ma, Kaili Xi, Yanfeng Wang, Tong Sci Rep Article Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study followed the guidelines of PRISMA and Cochrane handbook. The hazard ratios (HRs) for overall survival (OS) were pooled to estimate the main effect size. Twenty studies recruited a total of 5576 patients were available for this meta-analysis. The results showed that MYC (HR = 1.96, 95%CI (confidence interval) = 1.69–2.27)without heterogeneity(I(2) = 17.2%, P = 0.280), BCL2 (HR = 1.65, 95%CI = 1.43–1.89, I(2) = 20.7%, P = 0.234) protein overexpression, and co-overexpression (HR = 2.58, 95%CI = 2.19–3.04, I(2) = 17.2%, P = 0.275) had a poor prognosis in R-CHOP treated DLBCL patients, respectively. The current analysis indicated that MYC and/or BCL2 protein overexpression, and particularly co-overexpression was related to short overall survival in R-CHOP treated DLBCL patients, showing that application of the two new biomarkers can help to better stratify DLBCL patients and guide targeted treatment. Nature Publishing Group UK 2018-04-19 /pmc/articles/PMC5908914/ /pubmed/29674626 http://dx.doi.org/10.1038/s41598-018-24631-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Li, Lu
Li, Yanyan
Que, Ximei
Gao, Xue
Gao, Qian
Yu, Mingxing
Ma, Kaili
Xi, Yanfeng
Wang, Tong
Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title_full Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title_fullStr Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title_full_unstemmed Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title_short Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
title_sort prognostic significances of overexpression myc and/or bcl2 in r-chop-treated diffuse large b-cell lymphoma: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908914/
https://www.ncbi.nlm.nih.gov/pubmed/29674626
http://dx.doi.org/10.1038/s41598-018-24631-5
work_keys_str_mv AT lilu prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT liyanyan prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT queximei prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT gaoxue prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT gaoqian prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT yumingxing prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT makaili prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT xiyanfeng prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis
AT wangtong prognosticsignificancesofoverexpressionmycandorbcl2inrchoptreateddiffuselargebcelllymphomaasystematicreviewandmetaanalysis